Loading...
Symbols:
Loading...
Symbols:
ISIS Pharmaceuticals, Inc. (ISIS)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on ISIS Pharmaceuticals, Inc. (ISIS)
35 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on ISIS
- David Gordon(5)
- SA Editor Miriam Metzinger(5)
- Steven Turner (3)
- Ohad Hammer(3)
- Centient Biotech Investor(3)
Most popular authors
(tracked in watchlists)
- Bespoke Investment Group(534)
- Andrew Wilkinson(301)
- Stockerblog (157)
- SA Editor Joan Wickham(144)
- Zacks.com (118)
Most commented on authors
- Ohad Hammer(17)
- Michael Steinberg (13)
- Steven Turner (9)
- Freund Investing(8)
- SA Editor Miriam Metzinger(6)
- Isis Technology Used to Attack Brain Tumors
- Pfizer Needs Isis More Than Isis Needs Pfizer
- Even Fatter Yields for Pfizer; M&A Targets in the Sector
- 'When There's Blood in the Streets', Buy Biotech Stocks
- Biotech Names With Big Potential
- Isis Pharmaceuticals' Obesity Buster an Enormous Finding
- In Tech We Trust - Fast Money Recap (6/20/08)
- FDA Stings Pharma, Big and Small
- Investing in miRNA: Beware the Hype, Follow the Money
- Fast Money Recap - Oil Spoils Everything (6/6/08)
- Three Game-Changers For Big Pharma
- Six Significant Gene Therapy Stocks
- Isis Pharmaceuticals Panic Overdone
- Rosetta Genomics: Mining Genes From Junk (Part II)
- Fast Money Recap, 4/1/08: Gold Takes the Elevator
- Isis-Genzyme: Deal of the Year?
- ISIS Pharma Should Jump on 'Multiple Catalysts'
- A Volatile January for Financials, Healthcare
- Wal-Mart's Guidance Shows No Sign of Slow-Down, Good for Investors
- Pharma, Biotech Present Great Investment Opportunities in 2008
- A Win-Win for Isis, Genzyme in Cholesterol Drug Deal
- Tuesday's Options Report: CFC, Starbucks, ISIS, CVS, BUD, DFS
- VMware, Isis Pharma: Avoid Emotion in Market Swings
- A Bark Worse Than Its Bite
- Gaming Rules For Trading Biotech Stocks
- Differentiating Between Stocks and the Stock Market
- Companies With The Most Analyst Attention & Affection
-
Biotech Day In Review: Regeneron Up On AMD Data
on Mar 28, 2007
- Biotech Day in Review: Biosite Takes $85 Offer from Beckman Coulter
- Biotech Day In Review: Amgen Hit with SEC Investigation
- Biotech IPO Watch: Rosetta Genomics Using MicroRNAs for Diagnostics
- Eye on Alnylam: Silencing the Gene
- Expecting a Big Move in Isis Pharma
- Isis To Profit From Pfizer's Stumble
- Biotech IPO: Highlights from Rosetta Genomics' F1 Filing
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »